



RNAdestination™

Art to connect messenger RNA
and novel biotherapeutics



RNAdestination™

Unlock the potential of messenger RNA to develop novel biotherapeutics

In-Cell-Art is a French biopharmaceutical company specializing in the development of Nanotaxi® for macromolecular drugs (DNA, mRNA). Its founder and research team including a Nobel laureate designed new classes of vectors organized on a nanometric scale, which enable them to cross the cell barrier safely and efficiently.

One of our objectives is to tap into the potential of **messenger RNA** to produce proteins at reduced time and costs. Without fear of genomic integration, this novel approach can treat a wide range of diseases whose targets proteins were never accessible as drug candidate.


In-Cell-Art made several proof of concepts demonstrating Nanotaxi® can deliver **messenger RNA** inside cells and overcome its limited efficacy by not only dramatically increasing the level of expression but also modulating it to restore physiological conditions. This could also help to avoid unwanted adverse effect of uncontrolled protein expression as observe when delivering DNA molecules.

Our scientific team accumulates expertise in **mRNA** formulation, working in RN-ARMORVAX with Sanofi Pasteur and CureVac. Its objective is to develop a new universal **mRNA**-based vaccine technology platform with budget of US\$ 33.1 million co-financed by the USA Defense Advanced Research Projects Agency.


For our partners, **In-Cell-Art** can bring its highly technical competencies and unique resources in the discipline of nucleic acid delivery which have been developed over 20 years of research, and specific patents for proprietary formulations and targeting of nucleic acids to host cells in a controlled manner.

Messenger RNA to deliver? In-Cell-Art is your destination!!

A. Luciferase expression



B. Modulation of EPO expression



(A) Luciferase expression in muscle after injection of Nanotaxi®/mRNA. Luciferase was observed by bioluminescence at day 1. (B) Modulation of the hematocrit level in mice injected intramuscularly with Nanotaxi®/mRNA over a period of 6 months. At day 0 and 42, mice received treatment#1 and #2 consisting of 2 successive injections with one week interval of mRNA encoding murine EPO (mEPO) either naked (open triangles) or formulated with Nanotaxi®1 (solid squares) or Nanotaxi®2 (solid circles). At day 100 and 144, mice received respectively treatment#3 consisting of mEPO mRNA either naked or formulated with Nanotaxi®1 or Nanotaxi®2, and treatment#4 consisting of mEPO mRNA formulated with Nanotaxi®1. As control, mice were also uninjected (open squares). Dotted lines represent the fluctuation of the physiological hematocrit level.